icon3

Beta-Glucan applications

 

Biotec Pharmacon develops, manufactures and markets immune modulating compounds for the human health sectors through its wholly owned subsidiary Biotec BetaGlucans. Basic research on the mode of action of the various proprietary beta-1,3/1,6-glucan products at a cellular/molecular level has been the foundation for scientific experiments in animal models and in clinical trials. Experience over a period of almost 20 years has confirmed that beta-1,3/1,6-glucan enhances overall disease resistance and improves health. Studies have shown that pure beta-1,3/1,6-glucan is a non-toxic modulator of various immune functions in the body, and affects many immunity related disorders. Beta-1,3/1,6-glucan interacts with cells that control innate immune mechanisms and orchestrates other immune reactions, especially the macrophages. The product therefore has many applications within human medicine, including general infection prophylaxis, immune therapy of cancer, and to counteract various sufferings that are related to imbalanced immune responses.
Development programs within the following indications are running:
• Topical Wound application, in particular Diabetic Ulcer
• As an adjuvant for monoclonal based cancer treatment
• Inflammatory bowel disease (IBD)
The company seeks to capitalize on its comprehensive research base and IP portfolio.